Comments

Sonnet BioTherapeutics

SONNNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$0.852000
-0.0070-0.81%
At Close: -
$0.880000
0.033.29%
After Hours: 5:44 PM EDT
15 minutes delayed
Sonnet BioTherapeutics (SONN) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$30.00
Lowest Price Target1
$2.00
Consensus Price Target1
$8.53

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Sonnet BioTherapeutics (NASDAQ:SONN) Stock, Analyst Ratings, Price Targets, Forecasts

Sonnet BioTherapeutics Holdings Inc has a consensus price target of $8.53 based on the ratings of 7 analysts. The high is $30 issued by Chardan Capital on May 28, 2024. The low is $2 issued by BTIG on February 9, 2022. The 3 most-recent analyst ratings were released by Chardan Capital, EF Hutton, and Chardan Capital on May 28, 2024, May 16, 2024, and February 15, 2024, respectively. With an average price target of $22.33 between Chardan Capital, EF Hutton, and Chardan Capital, there's an implied 2437.88% upside for Sonnet BioTherapeutics Holdings Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Feb
0
0
0
0
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Chardan Capital
EF Hutton
Ladenburg Thalmann
EF Hutton
BTIG

1calculated from analyst ratings

Analyst Ratings for Sonnet BioTherapeutics

Buy NowGet Alert
05/28/2024Buy Now3309.09%Chardan Capital
Keay Nakae
$30 → $30MaintainsBuyGet Alert
05/16/2024Buy Now695.45%EF Hutton
Tim Moore
$11 → $7MaintainsBuyGet Alert
02/15/2024Buy Now3309.09%Chardan Capital
Keay Nakae
$75 → $30MaintainsBuyGet Alert
11/27/2023Buy Now695.45%Ladenburg Thalmann
Ahu Demir
 → $7Initiates → BuyGet Alert
08/23/2023Buy Now661.36%EF Hutton
Michael King
 → $147.4Assumes → BuyGet Alert
08/16/2023Buy Now1263.64%Chardan Capital
Keay Nakae
$308 → $264MaintainsBuyGet Alert
06/26/2023Buy Now661.36%EF Hutton
Michael King
 → $147.4ReiteratesBuy → BuyGet Alert
05/25/2023Buy Now661.36%EF Hutton
Michael King
 → $147.4Assumes → BuyGet Alert
05/11/2023Buy Now1490.91%Chardan Capital
Keay Nakae
$374 → $308MaintainsBuyGet Alert
04/19/2023Buy Now661.36%EF Hutton
Michael King
 → $147.4Reiterates → BuyGet Alert
04/19/2023Buy Now1831.82%Chardan Capital
Keay Nakae
$484 → $374MaintainsBuyGet Alert
02/15/2023Buy Now661.36%EF Hutton
Michael King
 → $147.4Reiterates → BuyGet Alert
12/19/2022Buy Now661.36%EF Hutton
Michael King
 → $147.4Initiates → BuyGet Alert
09/22/2022Buy Now2400%Chardan Capital
Keay Nakae
$44 → $484MaintainsBuyGet Alert
08/16/2022Buy Now127.27%Chardan Capital
Keay Nakae
$770 → $616MaintainsBuyGet Alert
02/09/2022Buy Now127.27%BTIG
Kaveri Pohlman
$1540 → $616MaintainsBuyGet Alert
12/20/2021Buy Now184.09%Chardan Capital
Keay Nakae
—MaintainsBuyGet Alert
12/16/2021Buy Now127.27%HC Wainwright & Co.
Michael King
—Initiates → BuyGet Alert
09/15/2021Buy Now468.18%BTIG——Initiates → BuyGet Alert

FAQ

Q

What is the target price for Sonnet BioTherapeutics (SONN) stock?

A

The latest price target for Sonnet BioTherapeutics (NASDAQ:SONN) was reported by Chardan Capital on May 28, 2024. The analyst firm set a price target for $30.00 expecting SONN to rise to within 12 months (a possible 3309.09% upside). 6 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Sonnet BioTherapeutics (SONN)?

A

The latest analyst rating for Sonnet BioTherapeutics (NASDAQ:SONN) was provided by Chardan Capital, and Sonnet BioTherapeutics maintained their buy rating.

Q

When was the last upgrade for Sonnet BioTherapeutics (SONN)?

A

There is no last upgrade for Sonnet BioTherapeutics

Q

When was the last downgrade for Sonnet BioTherapeutics (SONN)?

A

There is no last downgrade for Sonnet BioTherapeutics.

Q

When is the next analyst rating going to be posted or updated for Sonnet BioTherapeutics (SONN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on May 28, 2024 so you should expect the next rating to be made available sometime around May 28, 2025.

Q

Is the Analyst Rating Sonnet BioTherapeutics (SONN) correct?

A

While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a maintained with a price target of $30.00 to $30.00. The current price Sonnet BioTherapeutics (SONN) is trading at is $0.88, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch